Skip to content

Study · Animal study (in vivo) · horse · 2025

3 results

Administration study of somapacitan, a long-acting growth hormone derivative, in horse for doping control purpose.

Shimizu Y, Sugai-Bannai M, Tanabe H, Saito K, Ito H, Tokushige H, Kamiya K, Hirano-Kodaira M, Yamada M, Leung GN

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society25 Aug 2025

PMID40886666 (opens in a new tab)DOI10.1016/j.ghir.2025.101662 (opens in a new tab)PepBankPUB-40886666
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In thoroughbred mares, plasma IGF-1 increased significantly after somapacitan administration.

    In plain wordsIn horses, plasma IGF-1 increased from baseline after somapacitan administration.

    Peptide
    Somapacitan
    Outcome
    IncreasePlasma IGF-1
    Study

    horsen = 3

    Thoroughbred mares
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    90 mg · subcutaneousAs given in this study (horse).

    Source sentences

    Summary
    Plasma IGF-1 concentration significantly increased in all horses after administration of somapacitan.
    1 context sentence
    Summary · context
    Three thoroughbred mares were each administered 90 mg somapacitan subcutaneously.
  2. 02AnimalAnimal study (in vivo)Pharmacokinetics

    In thoroughbred mares given somapacitan, its specific T10 fragment was detected through 14 days and confirmed through 10 days.

    In plain wordsIn horses given somapacitan, its specific fragment was detected through 14 days and confirmed through 10 days.

    Peptide
    Somapacitan
    Outcome
    Not applicableSomapacitan-specific fragment detection
    Study

    horsen = 3

    Thoroughbred mares
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    90 mg · subcutaneousAs given in this study (horse).

    Measurements

    Detection window
    14 days
    Confirmation window
    10 days

    Source sentences

    Summary
    The somapacitan-specific T10 peptide fragment that allows discriminative identification of somapacitan and rhGH was detected up to 14 days and confirmed in post-administration samples collected up to 10 days.
    1 context sentence
    Summary · context
    Three thoroughbred mares were each administered 90 mg somapacitan subcutaneously.
  3. 03AnimalAnimal study (in vivo)Pharmacokinetics

    In thoroughbred mares given somapacitan, shared somapacitan and rhGH fragments were detected and confirmed in plasma 14 days after administration.

    In plain wordsIn horses given somapacitan, shared growth hormone fragments were detected and confirmed in plasma after 14 days.

    Peptide
    Somapacitan
    Outcome
    Not applicableShared fragment detection
    Study

    horsen = 3

    Thoroughbred mares
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    90 mg · subcutaneousAs given in this study (horse).

    Measurements

    Detection and confirmation
    14 days

    Source sentences

    Summary
    Several shared peptide fragments between somapacitan and rhGH were also detected and confirmed in plasma samples collected 14 days post-administration, supporting the applicability of the test strategy for the analysis of authentic doping control samples in horses.
    1 context sentence
    Summary · context
    Three thoroughbred mares were each administered 90 mg somapacitan subcutaneously.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.